Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000):: More alike than different!

被引:23
作者
Jones, RN [1 ]
Beach, ML
Pfaller, MA
机构
[1] JONES Grp, JMI Labs, N Liberty, IA USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Univ Iowa, Coll Med, Iowa City, IA USA
关键词
D O I
10.1016/S0732-8893(01)00287-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The spectrum and potency of ciprofloxacin, gatifloxacin and levofloxacin was compared to that of 10 other agents against urinary tract isolates of Pseudomonas aeruginosa among patients in the year 2000 SENTRY Antimicrobial Surveillance Program (Europe, Latin America, North America). Dramatic differences were observed between isolates in geographic areas with the most fluoroquinolone-resistant strains detected in Latin America (54.5% resistance) compared to resistance rates of 40.8-43.7% and 28.3-29.2% for Europe and North America, respectively. Overall, no significant differences were observed between the spectrums of these fluoroquinolones (37.1-38.8% resistance) for therapy of P. aeruginosa urinary tract infections in hospitalized patients. Generally, in this world wide sample, aminoglycosides, carbapenems (imipenem, meropenem), cefepime, and piperacillin with or without tazobactam possessed a wider range of activity and spectrum versus current P. aeruginosa clinical isolates. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:161 / 163
页数:3
相关论文
共 13 条
[1]   Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999:: Role of target enzyme in mechanism of fluoroquinolone resistance [J].
Akasaka, T ;
Tanaka, M ;
Yamaguchi, A ;
Sato, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2263-2268
[2]  
ALES AC, 2001, CLIN INFECT DIS S2, V32, pS146
[3]  
[Anonymous], M100S11 NCCLS
[4]   Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998) [J].
Gales, AC ;
Jones, RN ;
Gordon, KA ;
Sader, HS ;
Wilke, WW ;
Beach, ML ;
Pfaller, MA ;
Doern, GV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) :295-303
[5]  
GUPA K, 2001, CLIN INFECT DIS, V33, P89
[6]  
GUPTA K, 1999, JAMA-J AM MED ASSOC, V381, P736
[7]  
Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522
[8]  
Karlowsky JA, 2001, J ANTIMICROB CHEMOTH, V47, P23
[9]  
MATHAI D, 2001, IN PRESS DIAGN MICRO, V40
[10]  
National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS